Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
出版年份 2019 全文链接
标题
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
作者
关键词
-
出版物
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2019-01-16
DOI
10.1093/neuonc/noz015
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
- (2018) Malte Mohme et al. CLINICAL CANCER RESEARCH
- T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
- (2018) Karolina Woroniecka et al. CLINICAL CANCER RESEARCH
- Temozolomide for immunomodulation in the treatment of glioblastoma
- (2018) Aida Karachi et al. NEURO-ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma
- (2018) Carter M. Suryadevara et al. OncoImmunology
- Serial changes in lymphocyte subsets in patients with newly diagnosed high grade astrocytomas treated with standard radiation and temozolomide
- (2017) Jian L. Campian et al. JOURNAL OF NEURO-ONCOLOGY
- Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
- (2017) Maria-Carmela Speranza et al. NEURO-ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme
- (2017) Sabrina Heynckes et al. Oncotarget
- Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
- (2017) Anna C. Filley et al. Oncotarget
- Immune targets and neoantigens for cancer immunotherapy and precision medicine
- (2016) Rong-Fu Wang et al. CELL RESEARCH
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
- (2016) D. Mathios et al. Science Translational Medicine
- Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
- (2016) T. M. Johanns et al. Cancer Discovery
- Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas
- (2015) Jian L. Campian et al. JOURNAL OF NEURO-ONCOLOGY
- Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
- (2015) Duane A. Mitchell et al. NATURE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
- (2015) D. A. Reardon et al. Cancer Immunology Research
- Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas
- (2015) Catherine Flores et al. OncoImmunology
- Temozolomide Does Not Impair Gene Therapy-Mediated Antitumor Immunity in Syngeneic Brain Tumor Models
- (2014) M. Candolfi et al. CLINICAL CANCER RESEARCH
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion
- (2013) Sara Fritzell et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide
- (2013) Luis Sanchez-Perez et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
- (2013) Laura Ridolfi et al. Journal of Translational Medicine
- Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models
- (2013) Ling Cen et al. NEURO-ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice
- (2013) Luis A. Sanchez-Perez et al. PLoS One
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
- (2012) Guangchuang Yu et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Monoclonal antibody blockade of IL-2 receptor during lymphopenia selectively depletes regulatory T cells in mice and humans
- (2011) D. A. Mitchell et al. BLOOD
- ggplot2: Elegant Graphics for Data Analysis
- (2011) Cedric Ginestet JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY
- Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
- (2011) D.-S. Kong et al. NEURO-ONCOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
- (2009) Claire Banissi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance
- (2009) S. Yip et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
- (2009) Jennifer L. Clarke et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started